Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 19;10:2986. doi: 10.1038/s41598-020-59818-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

GB235 in combination with Trastuzumab reversed resistance induced by heregulin-α in BT-474 cells by the restraining heregulin-α/HER3 pathway. (A) In the presence of exogenous heregulin-α, the BT-474 cells were resistant to Trastuzumab. With the addition of GB235 to Trastuzumab, BT-474 cells recovered sensitivity to Trastuzumab. The data are expressed as the mean ± SEM of three independent experiments. ***p < 0.001. (B) Serum-starved BT-474 cells pretreated with GB235 (20 µg/mL), Trastuzumab (20 µg/mL) alone or in combination, then stimulated by heregulin-α, and immunoblotted.